Culture

AI shows public attitude toward COVID-19 is more 'infectious' than disease itself

CHICAGO --- Public attitude toward COVID-19 and its treatments is more "infectious" than the disease itself, according to a new Northwestern Medicine study using Artificial Intelligence (AI) to analyze tweets about the virus. Researchers studied the influence of Twitter on COVID-19 health beliefs as well as the competing influence of scientific evidence versus the speeches of politicians.

The study's key findings:

People's biases are magnified when they read tweets about COVID-19 from other users, and the more times it has been retweeted, the more they tend to believe it and retweet it themselves.

Scientific events, such as scientific publications, and non-scientific events, such as speeches of politicians, equally influence health belief trends on social media.

"In the pandemic, social media has contributed to much of the information and misinformation and bias of the public's attitude toward the disease, treatment and policy," said corresponding study author Yuan Luo, chief Artificial Intelligence officer at the Institute for Augmented Intelligence in Medicine at Northwestern University Feinberg School of Medicine.

"Our study helps people to realize and re-think the personal decisions that they make when facing the pandemic," Luo said. "The study sends an 'alert' to the audience that the information they encounter daily might be right or wrong, and guide them to pick the information endorsed by solid scientific evidence. We also wanted to provide useful insight for scientists or health care providers, so that they can more effectively broadcast their voice to targeted audiences."

The study was published recently in the Journal of Medical Internet Research.

How can scientists counter inaccurate information from politicians?

"Politicians may talk inaccurately about a certain treatment's effectiveness or say that COVID-19 is no big deal; it's just like the flu," said Luo said, also chief AI officer at Northwestern University Clinical and Translational Sciences Institute. "These comments have as strong effect as real scientific evidence and drive people's beliefs. This is what we are concerned about."

By understanding how the public's attitudes are affected, scientists can take actions to make sure scientific fact and evidence have a loud enough voice.

"As a scientist, you need to be aware that you need to get the science out to people. If you don't put energy into this, your efforts can be easily offset by those who talk irresponsibly," Luo said. "Going forward, we may want to pay more attention to a public information campaign to educate people about the vaccine in order to maximize the inoculation impact."

How are people's attitudes toward COVID-19 influenced by tweets?

"As a lay person, you should become aware of what you retweet and do a fact check first," Luo said. "And be aware anything you see on Twitter is shaping your attitude. You need to become aware of this before you let others' tweets and opinions shape yours and you become part of that megaphone."

"A lot of people aren't aware of how much their beliefs are impacted by tweets, and don't bother to fact check what they read and retweet. When the information is biased, they ignore or did not notice it. It's like a viral marketing effect. It's just about catching eyeballs on a trending topic, but it affects everyone on social media."

How is this study novel?

The study is novel because it integrates machine learning algorithms and classic epidemiology models to retrospectively investigate the contents on social media and its effects, Luo said.

The study also allows other researchers to "look under the hood" to understand how this AI algorithm works.

Machine learning and deep learning algorithms are usually opaque, blackbox mechanisms. But in this study, investigators paid special attention to improve the model's interpretability.

"We identified the fluctuating trends of public attitudes from the tweets, then aligned the important scientific and non-scientific events that are associated with these trends," Luo said. "As a result, we are offering insights people can take action on."

How many tweets did the AI analyze?

Luo's team, led by the study's first author Hanyin Wang, a Ph.D. student in the Driskill Graduate Program, retrospectively collected COVID-19-related tweets using the Twitter API. In total, they retrieved 92,687,660 tweets corresponding to 8,967,986 users from January 6 to June 21, 2020. To train the AI model, they randomly selected 5,000 of the tweets for annotation. Each tweet was doubly reviewed to decide if it met any of the four core constructs of the health belief model, perceived susceptibility, perceived severity, perceived benefits and perceived barriers.

Next step: using AI to analyze how social media affects attitudes toward COVID-19 vaccines

Luo's team is currently integrating machine learning and deep learning in the study of how social media can affect the general public's attitude toward COVID-19 vaccines. The goal is to identify specific public concerns and inform targeted vaccination campaigns to maximize inoculation impact. They are also looking at using social media data as a way to detect gender or race disparities in and out of the pandemic.

Credit: 
Northwestern University

Goodbye UTIs: Duke scientists develop vaccine strategy for urinary tract infections

image: Immune cells (green) infiltrating the bladder lining (red) to fight off invading bacteria. Blue areas are nuclei of other bladder tissue cells

Image: 
Duke Health

DURHAM, N.C. - Anyone who has ever developed a urinary tract infection (UTI) knows that it can be painful, pesky and persistent. UTIs have a high recurrence rate and primarily afflict women -- as many as 50% of women will experience at least one UTI during their lifetime.

However, what if patients could take a vaccine that would prevent future UTIs? In a March 1 study in the Proceedings of the National Academy of Sciences, Duke researchers describe a new vaccination strategy that they think could re-program the body to fight off the bacteria that cause urinary tract infections.

"Although several vaccines against UTIs have been investigated in clinical trials, they have so far had limited success," said Soman Abraham, Ph.D., Grace Kerby Distinguished Professor of Pathology, Immunology and Molecular Genetics & Microbiology in the School of Medicine and senior author on the paper.

"There are currently no effective UTI vaccines available for use in the U.S. in spite of the high prevalence of bladder infections," Abraham said. "Our study describes the potential for a highly effective bladder vaccine that can not only eradicate residual bladder bacteria, but also prevent future infections."

The strategy, which the team showed to be effective in mouse models, involves re-programming an inadequate immune response that the team identified last year. They observed that when mouse bladders get infected with E. coli bacteria, the immune system dispatches repair cells to heal the damaged tissue, while launching very few warrior cells to fight off the attacker. This causes bacteria to never fully clear, living on in the bladder to attack again.

According to lead author Jianxuan Wu, Ph.D., who recently earned his doctorate from the Department of Immunology at Duke, "the new vaccine strategy attempts to 'teach' the bladder to more effectively fight off the attacking bacteria. By administering the vaccine directly into the bladder where the residual bacteria harbor, the highly effective vaccine antigen, in combination with an adjuvant known to boost the recruitment of bacterial clearing cells, performed better than traditional intramuscular vaccination."

The researchers reported that bladder-immunized mice effectively fought off infecting E. coli and eliminated all residual bladder bacteria, suggesting the site of administration could be an important consideration in determining the effectiveness of a vaccine.

"We are encouraged by these findings, and since the individual components of the vaccine have previously been shown to be safe for human use, undertaking clinical studies to validate these findings could be done relatively quickly," Abraham said.

Credit: 
Duke University Medical Center

Natural product isolated from sea sponge tested against cancer cells

image: FEFU lab for DNA diagnostics, equipment

Image: 
FEFU press office

Scientists from Far Eastern Federal University (FEFU) together with Russian and German colleagues, continue studying antitumor compounds synthesized based on bioactive molecules isolated from a sea sponge. One of them fights cancer cells resistant to standard chemotherapy, and at the same time has an interesting dual mechanism of action. A related article appears in Marine Drugs.

Scientists have tested the biological effect of the marine alkaloid 3,10-dibromofascaplysin on various prostate cancer cells, including those resistant to standard docetaxel-based chemotherapy. The compound was first isolated from the sea sponge Fascaplysinopsis reticulata and subsequently chemically synthesized in FEFU. The substance forces tumor cells to die via a programmed cell death mechanism. This process is called "apoptosis" and is considered the most favorable mode of action of anticancer drugs.

"The examined compound, while killing cancer cells, even ones resistant to standard chemotherapy, simultaneously activates an enzyme (so-called &laquokinase») protecting these tumor cells. However, it can't be considered as a "good" or "bad" effect. This is just a mechanism of action, an understanding of which suggests us to apply 3,10-dibromofascaplysin together with inhibitors of these enzymes," says Dr. Sergey Dyshlovoy, from the Laboratory of biologically active substances of FEFU School of Natural Sciences, senior researcher in the laboratory of the pharmacology of National Scientific Centre of Marine Biology (Vladivostok, Russia).

According to the scientist, the synthesized compound in addition to its own activity, works well in combination with several already approved anticancer drugs, enhancing their antitumor effect.

Next, scientists are planning to examine how 3,10-dibromofascaplysin affects non-cancer cells. They already run a related project supported by the Russian Foundation for Basic Research, aiming to report the outcomes during 2021.

"Fascaplysins are rather toxic to non-cancer cells. In our laboratory, we are trying to modify the structure of these compounds in order to reduce their cytotoxic effect on normal cells, while maintaining the necessary antitumor effect. The goal is to create a substance for targeted therapy, with a minimum of side effects for healthy cells of the body," says Dr. Maxim Zhidkov, Head of Department of Organic Chemistry, FEFU School of Natural Sciences.

Commented on the time needed for the development of the on-the-shelf drug, scientists speak about the horizon of 10-15 years, given the necessity for long preliminary and further clinical trials.

Credit: 
Far Eastern Federal University

New MHRP pre-clinical SHIV remission study shows progress in delaying viral load rebound

SILVER SPRING, Md. - A recent preclinical study by U.S. Military HIV Research Program (MHRP) researchers showed that an experimental therapy combining a TLR7 agonist and two broadly neutralizing antibodies delayed viral rebound in SHIV-infected macaques after antiretroviral therapy (ART) interruption.

The experimental combination therapy consisted of TLR7 agonist GS-986 and two broadly neutralizing antibodies (bnAbs), N6-LS and PGT121, targeting different regions of the HIV envelope. The rhesus macaques were initiated on viral suppressive antiretroviral therapy 14 days post infection, a timespan from infection to treatment which mirrors what is feasible in acute HIV infection. Researchers then administered the experimental combination therapy, followed by ART pause and measured how long it took for SHIV viral load to rebound.

"This study demonstrated that the combination of TLR7 agonist and dual bnAbs delayed viral rebound after ART interruption by 2-fold," said Dr. Denise Hsu, MHRP Associate Director of Therapeutics. "This approach may represent a potential strategy to target the HIV reservoir in HIV-infected individuals."

A critical barrier to curing HIV is the reservoir of latent virus that remains hidden and infects cells throughout the body, leading to viral rebound in the vast majority of HIV-infected individuals after they discontinue ART. The hypothesis behind this strategy is that an agent such as the TLR7 agonist, bolstered by therapeutic bnAbs, can stimulate the immune system to clear latent HIV. The paper was published in PLOS Pathogens.

MHRP, part of the Walter Reed Army Institute of Research, collaborates with the Thai Red Cross AIDS Research Centre in Bangkok to identify acutely infected individuals and immediately start them on ART in a study called RV254. For the last few years, small clinical trials within this cohort have evaluated strategies aimed at inducing a cure or long-term remission of HIV. Interventions are wide-ranging and include therapeutic HIV vaccines and broadly neutralizing antibodies.

During these studies, volunteers are taken off ART to test the effects of a candidate intervention. This method, called analytical treatment interruption (ATI), looks at the time it takes for the viral load to rebound after the interruption. Participants are followed closely and restart ART when viral load rises to a certain threshold.

According to Dr. Sandhya Vasan, HJF Director for MHRP, "While we have seen some promise in our ATI trials, it has become clear that we need a combination intervention strategy to generate longer lasting viral suppression."

Based on these new preclinical data and building, MHRP hopes to evaluate the combination of innate immune stimulation, active and passive immunization for the induction of HIV remission in early treated people living with HIV.

https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009339

Credit: 
The U.S. Military HIV Research Program (MHRP)

Why some melanoma patients do not respond to immunotherapy

NEW YORK, NY (March 1, 2021)--By harnessing the immune system against cancer, immunotherapies have revolutionized the way some types of cancer are treated. But most patients--across cancer types--do not respond, and in most cases, scientists are at a loss as to why.

Researchers at Columbia and MIT have created a new technique that can uncover nearly all of the tricks cancer cells use to evade immunotherapies, which could lead to the development of more effective treatments.

The researchers tested their new technique with cancer cells and matching immune cells from melanoma patients and identified previously unknown resistance mechanisms to immune checkpoint inhibitors, a powerful and widely used class of immunotherapy drugs.

The findings were published online March 1 in Nature Genetics.

Immunotherapies fail or stop working in two-thirds of melanoma patients  

Immune checkpoint inhibitors are drugs that are designed to release the "brakes" that prevent the immune system from operating at full power and attacking the cancer cells.

"With drugs called immune checkpoint inhibitors, we're now getting as close as we have ever been to curing one-third of patients with metastatic melanoma, even at a stage when the disease has spread throughout the body," says study leader Benjamin Izar, MD, PhD, assistant professor of medicine at Columbia University Vagelos College of Physicians and Surgeons.

"So the question is, what is happening in the other two-thirds of patients?" Izar says. "What are the mechanisms of intrinsic or adaptive drug resistance?"

In a previous study published in Cell in 2018, Izar and his team identified 250 genes in metastatic melanoma cells that allow them to evade the immunotherapy. The new study was devised to provide a systematic way to functionally decipher how each of those genes contributes to immunotherapy resistance. 

First Test of CRISPR Tool

The study is the first test of a new tool that combines two advanced technologies--CRISPR gene editing and single-cell RNA and -protein sequencing--in a way that allows researchers to determine the full landscape of how cancer cells can evade the immune system.

Using CRISPR, the researchers inactivated those 250 genes--one by one but in a pooled fashion--to create a mixture of 250 batches of melanoma cells, each with a different mutation. The entire heterogenous population of "edited" cancer cells was then exposed to T cells--the immune cells unleashed by checkpoint inhibitors in patients. 

Cells that resisted being killed by T cells were isolated, and a snapshot of all active processes within these cells was measured using single-cell RNA and protein profiling, providing a high-resolution molecular map of several gene perturbations resulting in immune escape.

"Our approach is unique in that we study these mechanisms in patient-derived models, and rather than looking at how a gene changes a cell's phenotype one gene at a time, we were able to study many genes with potential roles in drug resistance in patients in one sweep. It's the first time that such tools have been used at such a large scale," says Izar.

All told, close to a quarter million cells were analyzed. Computational biology tools, developed by Izar and co-senior author Aviv Regev, PhD, professor of biology at MIT, were employed to make sense of this tremendous data set.

New and Old Resistance Mechanisms Identified

The analysis identified new mechanisms of resistance to immunotherapy along with mechanisms that were previously known. "Basically, we recovered the majority of known mechanisms described over the last 10 years--validating that our approach works and giving us confidence that the new findings are important," Izar says.

"We also uncovered many new mechanisms of resistance," says Johannes C. Melms, MD, a postdoctoral fellow in the Izar lab and the study's co-first author (with Chris J. Frangieh, a doctoral student at MIT). 

One of the new resistance mechanisms involves a gene called CD58. "Our data suggests that loss of CD58 in melanoma cells confers immune escape through three potential mechanisms: impairing activation of T cells, reducing the ability of T cells getting into the tumor, and increasing the production of PD-L1," Melms says. "Because the CD58 gene is not mutated per se but rather just turned off, it raises the possibility that therapies that turn it on could overcome drug resistance in some patients." 

The researchers plan to develop therapies to improve response to immunotherapies based on this finding. 

Izar and his team expect to learn more about resistance to immunotherapy from the study data. "CD58 is just one of many genes that warrant a closer look," Izar says.

In future experiments, the researchers plan to inactivate various combinations of cancer cell genes at once. "In this study, we looked at what happens to cells when only one gene is inactivated," he says. "But it's likely that no single gene is sufficient to confer all the types of resistance to immunotherapy that we see in clinical practice."

The study focused on melanoma, but the same approach could be used to study resistance to immunotherapy in many other forms of cancer, the researchers note. 

Credit: 
Columbia University Irving Medical Center

4D bioengineering materials bend, curve like natural tissue

image: 4D hydrogel-based materials can undergo multiple conformational shape changes in response to environmental cues

Image: 
Aixiang Ding

Tissue engineering has long-depended on geometrically static scaffolds seeded with cells in the lab to create new tissues and even organs. The scaffolding material -- usually a biodegradable polymer structure -- is supplied with cells and the cells, if supplied with the right nutrients, then develop into tissue as the underlying scaffold biodegrades. But this model ignores the extraordinarily dynamic morphological processes that underlie the natural development of tissues.

Now, researchers at the University of Illinois Chicago have developed new 4D hydrogels -- 3D materials that have the ability to change shape over time in response to stimuli -- that can morph multiple times in a preprogrammed or on-demand manner in response to external trigger signals.

In a new Advanced Science study, the UIC researchers, led by Eben Alsberg, show that these new materials may be used to help develop tissues that more closely resemble their natural counterparts, which are subject to forces that drive movement during their formation.

"The hydrogels can be programmed or induced to undergo multiple controllable shape changes over time. This strategy creates experimental conditions to partially mimic or stimulate the continuous different shape changes that developing or healing tissues undergo, and it may let us study morphogenesis and also help us engineer tissue architectures that more closely resemble native tissues," said Alsberg, the Richard and Loan Hill Professor of Biomedical Engineering and corresponding author on the paper.

The novel material is made up of different hydrogels that swell or shrink at different rates and extents in response to water or the concentration of calcium. By creating complex layering patterns, the researchers can guide the conglomerate material to bend one way or another as the layers swell and/or shrink.

"We can change the shape of these materials by adjusting, for example, the amount of calcium present," said Alsberg, who also is professor of orthopaedics, pharmacology and mechanical and industrial engineering at UIC.

In their experiments, the researchers were able to cause the hydrogel to form into pockets similar in shape to alveoli, the tiny sac-like structures in the lung where gas exchange takes place.

Not only are Alsberg's hydrogels able to change their architecture multiple times, but they also are highly cytocompatible, which means they can have incorporated cells and the cells remain alive -- something that many existing 4D materials are unable to do.

"We are really looking forward to pushing the limits of what our unique hydrogel systems can do in terms of tissue engineering," said Aixiang Ding, postdoctoral research associate at UIC and co-first author on the paper. UIC's Oju Jeon, research professor, is also a co-first author.

Credit: 
University of Illinois Chicago

Deep dive into bioarchaeological data reveals Mediterranean migration trends over 8,000 years

image: Thomas Leppard is an assistant professor of anthropology at Florida State University.

Image: 
FSU Photography Services

A team of international researchers led by a Florida State University assistant professor has analyzed reams of data from the Neolithic to Late Roman period looking at migration patterns across the Mediterranean and found that despite evidence of cultural connections, there's little evidence of massive migration across the region.

"Because of the prevailing scholarly attitude of the 'connected' Mediterranean -- one with high degrees of mobility and migration that drive the archaeological patterns we see -- we'd imagined we'd see comparatively high levels of migration reflected in the strontium isotope data," said Thomas Leppard, assistant professor of anthropology at Florida State. "That instead we saw low levels of migration, and that these in fact decreased over time, was very surprising."

Leppard and his colleagues found that from about 7,500 BC to AD 500, migration rates ranged from about 6% to 9% of the population within the dataset. These rates seem to have decreased over time.

The research is published in the Journal of Mediterranean Archaeology.

Many historians and archaeologists consider the Mediterranean basin to have been interconnected for much of its history. However, that theory is largely built on material culture that suggests such connections - for example, Greek-looking pots in Sicily in the Late Bronze Age, Arabic coins in Medieval Sardinia, or Roman-style dining sets in 2nd century AD Portugal.

Leppard wondered if the same pattern would be obvious if they brought human biochemistry into the mix.

For several years, scientists have been able to understand individual life histories by analyzing the chemistry of human remains. In humans, bodily tissues, including most bones, remake themselves constantly so that their chemical composition reflects their current environment. However, dental enamel and a small skull bone called the petrous portion are extremely hard and don't remodel, so once a human reaches adulthood, the isotope ratios in those two areas of the body don't change.

"As a result, if you spend childhood somewhere, and then move as an adult to a different place with different underlying chemistry, we can see a difference in the chemistry - and critically in the ratios of different strontium isotopes - between your dental enamel and your other bones," Leppard said. "If, however, you grew up and died in the same location, the ratios will be the same. That means we can start to quantify percentages of locals, and percentages of nonlocals in a given area."

Archaeologists have employed this technique for a while in the Mediterranean, but the sample sizes are generally very small because the experiments are expensive and there often aren't many samples of human remains. Leppard and his colleagues compiled all the data from many smaller experiments capturing a large time frame and re-analyzed it.

He cautioned that this is a starting place to assess the migration patterns of this region.

"It's important to say that migration is only one aspect of human mobility; we can't access seasonal or habitual mobility with this method, for example," Leppard said. "That said, we thought this would be a powerful method for assessing large-scale trends in Mediterranean migration across time. That these trends don't really match the current scholarship should generate productive debate and prompt new research."

Credit: 
Florida State University

Predicting microbial interactions in the human gut

image: Graduate student Veronika Dubinkina of Bioengineering, Professor of Bioengineering and Bliss faculty scholar Sergei Maslov, MIT postdoctoral fellow Akshit Goyal, and graduate student Tong Wang of Physics.

Image: 
Julia Pollack, University of Illinois.

The human gut consists of a complex community of microbes that consume and secrete hundreds of small molecules--a phenomenon called cross-feeding. However, it is challenging to study these processes experimentally. A new study, published in Nature Communications, uses models to predict cross-feeding interactions between microbial species in the gut. Predictions from such computational methods could eventually help doctors get a more complete understanding of gut health.

The microbial community, or microbiome, of the gut is known to influence human health. Previous studies have focused on determining the types of microbes that are present. Unfortunately, this information is not enough to understand the microbiome.

"The gut environment is shaped by small molecules known as metabolites, which are excreted by the microbial community," said Sergei Maslov (BCXT/CABBI), a professor of bioengineering and Bliss faculty scholar. "Although it is possible to measure these metabolites experimentally, it is cumbersome and expensive."

The researchers had previously published a study where they used experimental data from other studies to model the fate of metabolites as they pass through the gut microbiome. In the new study, they have used the same model to predict new microbial processes that have not been determined before.

"What we eat passes into our gut, and there is a cascade of microbes which release metabolites," said Akshit Goyal, a postdoctoral fellow at MIT and a collaborator of the Maslov lab. "Biologists have measured these molecules in human stools, we have shown that you can use computational models to predict the levels of some."

Measuring every metabolite and trying to understand which microbe might be releasing it can be challenging. "There is a large universe of possible cross-feeding interactions. Using this model, we can aid experiments by predicting which ones are more likely to occur in the gut," Goyal said.

The model was also supported by genomic annotations, which explain which microbial genes are responsible for processing the metabolites. "We are confident of our modelling predictions because we also checked whether the microbes contain the genes necessary for carrying out the associated reactions. About 65% of our predictions were supported by this information," said Veronika Dubinkina, a PhD student in bioengineering.

The researchers are now working to improve the model by including more experimental data. "Different people have different strains of gut microbes. Although these different strains have many genes in common, they differ in their capabilities," Dubinkina said. "We need to collect more data from patients to understand how different microbial communities behave in different hosts."

"We are also interested in determining how fast the microbes consume and secrete the metabolites," said Tong Wang, a PhD student in physics. "Currently the model assumes that all the microbes consume metabolites at the same rate. In reality, the rates are different and we need to understand them to capture the metabolite composition in the gut."

Credit: 
Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign

Through the looking glass: Artificial 'molecules' open door to ultrafast polaritonic devices

Researchers from Skoltech and the University of Cambridge have shown that polaritons, the quirky particles that may end up running the quantum supercomputers of the future, can form structures behaving like molecules - and these "artificial molecules" can potentially be engineered on demand. The paper outlining these results was published in the journal Physical Review B Letters.

Polaritons are quantum particles that consist of a photon and an exciton, another quasiparticle, marrying light and matter in a curious union that opens up a multitude of possibilities in next-generation polaritonic devices. Alexander Johnston, Kirill Kalinin and Natalia Berloff, professor at the Skoltech Center for Photonics and Quantum Materials and University of Cambridge, have shown that geometrically coupled polariton condensates, which appear in semiconductor devices, are capable of simulating molecules with various properties.

Ordinary molecules are groups of atoms bound together with molecular bonds, and their physical properties differ from those of their constituent atoms quite drastically: consider the water molecule, H2O, and elemental hydrogen and oxygen. "In our work, we show that clusters of interacting polaritonic and photonic condensates can form a range of exotic and entirely distinct entities - "molecules" - that can be manipulated artificially. These "artificial molecules" possess new energy states, optical properties, and vibrational modes from those of the condensates comprising them," Johnston, of the University of Cambridge Department of Applied Mathematics and Theoretical Physics, explains.

When researchers were running numerical simulations of two, three, and four interacting polariton condensates, they noticed some curious asymmetric stationary states in which not all of the condensates have the same density in their ground state. "Upon further investigation, we found that such states came in a wide variety of different forms, which could be controlled by manipulating certain physical parameters of the system. This led us to propose such phenomena as "artificial polariton molecules" and to investigate their potential uses in quantum information systems," Johnston says.

In particular, the team focused on an "asymmetric dyad", which consists of two interacting condensates with unequal occupations. When two of those dyads are combined into a tetrad structure, the latter is, in some sense, analogous to a homonuclear molecule - for instance, to molecular hydrogen H2. Furthermore, artificial polariton molecules can also form more elaborate structures, which could be thought of as "artificial polariton compounds."

"There is nothing preventing more complex structures from being created. Indeed, in our work we have found that there is a wide range of exotic, asymmetric states possible in tetrad configurations. In some of these, all condensates have different densities (despite all of the couplings being of equal strength), inviting an analogy with chemical compounds," Alexander Johnston notes.

In specific tetrad structures, each asymmetric dyad can be viewed as an individual "spin," defined by the orientation of the density asymmetry. This has interesting consequences for the system's degrees of freedom (the independent physical parameters required to define states); the "spins" introduce a discrete degree of freedom, in addition to the continuous degrees of freedom given by the condensate phases.

The relative orientation of each of the dyads can be controlled by varying the coupling strength between them. Since quantum information systems can potentially have increased accuracy and efficiency if they utilize some kind of hybrid discrete-continuous system, the team therefore proposed this hybrid tetrad structure as a potential basis for such a system.

"In addition, we have discovered a plethora of exotic asymmetric states in triad and tetrad systems. It is possible to seamlessly transition between such states simply by varying the pumping strength used to form the condensates. This property suggests that such states could form the basis of a polaritonic multi-valued logic system, which could enable the development of polaritonic devices that dissipate significantly less power than traditional methods and, potentially, operate orders of magnitude faster," Professor Berloff says.

Credit: 
Skolkovo Institute of Science and Technology (Skoltech)

Supertest evaluates performance of engineering students in Russia, the United States, India, China

image: Igor Chirikov, Affiliated Researcher at the HSE Institute of Education

Image: 
Igor Chirikov

A group of researchers representing four countries summed up the results of the Supertest, a large-scale study of the academic performance of engineering students in Russia, China, India, and the United States. It is the first study to track the progress of students in computer science and electrical engineering over the course of their studies with regard to their abilities in physics, mathematics, and critical thinking and compare the results among four countries. The article about study in Nature Human Behavior.

The HSE Institute of Education played a key role not only in collecting and analyzing data from Russia, but also in developing uniform assessment tools in mathematics and physics for all countries. The Institute conducted a full range of psychometric studies in addition to substantiating the quality of the measurements and the comparability of results across different countries.

The Supertest was initiated by Stanford University in partnership with HSE University Moscow, the Educational Testing Service (ETS), and universities in China and India. The study authors include Prashant Loyalka, an Associate Professor at Stanford University and a leading researcher at the HSE International Laboratory for Evaluating Practices and Innovations in Education; Igor Chirikov a senior researcher at the Center for Studies in Higher Education at UC Berkeley and an affiliated researcher of the HSE Institute of Education; and Elena Kardanova and Denis Federyakin , leading researchers at the Centre for Psychometrics and Measurements in Education at the HSE.

More than 30,000 undergraduate students participated in the study. The researchers collected a sample of students from elite and large universities, roughly equal in number for each country. In Russia, the sample included students from six Project 5-100 universities and 28 other universities. Their skill development was measured three times: upon entering university, at the end of their second year, and at the end of their studies.

The task of the specialists of the HSE Centre for Psychometrics and Measurements in Education was to develop tests that had questions that would be neutral for students of different countries and would yield adequately comparable results across different countries. 'Over the course of analyzing the test results, we have proven that we were able to achieve both tasks,' said Centre Director Elena Kardanova. 'Testing in different countries was conducted in accordance with the same rules, with the assistance of specially trained examiners. All students were offered the same incentives to participate. We additionally tested the sensitivity of the results to possible differences in student motivation.'

The Supertest showed that at the start of their studies, Russian students perform lower than Chinese students in mathematics and physics, but higher than students from India in mathematics. After two years of study, the gap between Russian and Chinese students narrows, while Indian students catch up with Russian students in mathematics.

One finding of the study that is cause for concern relates to engineering students' critical thinking skills. Initially, upon entering university, Russian engineering students outperform Indian students while performing lower than Chinese students. In terms of developing these skills over the course of their studies, students of all three countries perform lower than students in the United States. 'We found that, as the students progress in their studies, their critical thinking skills remain approximately the same in Russia and India, but significantly decrease in China. On the contrary, American students show improvement,' said Igor Chirikov. This is a serious problem, the researchers note, because technologies change rapidly, and in order to be able to master new ones, you need not only a firm grasp of the subject area, but, above all, skills of the 21st century.

Another unexpected result was the gradual decline of academic skills among engineering students in China. 'Students at Chinese universities have an extremely high level of skills upon enrollment, but over the course of their university studies this level decreases: this applies to physics, mathematics, and critical thinking. We observe this at both elite and large universities, albeit to different extents,' said Igor Chirikov. 'A possible explanation lies in the way undergraduate education is organized in China, where institutions put emphasis on lectures, and instructors are not as demanding as in Russia and India. As a result, students have less motivation to learn and are not held accountable for developing skills.'

The results of the Supertest provide insight into how graduates perform in the globally competitive market of future computer science and electronic engineering professionals. Each represented country is renowned for its engineering expertise, and it is the Chinese, American, Russian and Indian specialists who migrate to different countries that largely determine the technological progress around the world. The balance of power in this sphere of education can play a decisive role in who will win the technology race tomorrow.

Credit: 
National Research University Higher School of Economics

Swapping alpha cells for beta cells to treat diabetes

image: At left is a healthy islet with many insulin-producing cells (green) and few glucagon-producing cells (red). At right, this situation is altered in a diabetic islet with a heavy preponderance of glucagon-producing cells (red) and very few insulin-producing cells (green

Image: 
UT Southwestern Medical Center

Blocking cell receptors for glucagon, the counter-hormone to insulin, cured mouse models of diabetes by converting glucagon-producing cells into insulin producers instead, a team led by UT Southwestern reports in a new study. The findings, published online in PNAS, could offer a new way to treat both Type 1 and Type 2 diabetes in people.

More than 34 million Americans have diabetes, a disease characterized by a loss of beta cells in the pancreas. Beta cells produce insulin, a hormone necessary for cells to absorb and use glucose, a type of sugar that circulates in the blood and serves as cellular fuel.

In Type 2 diabetes, the body's tissues develop insulin resistance, prompting beta cells to die from exhaustion from secreting excess insulin to allow cells to take in glucose. In Type 1 diabetes, which affects about 10 percent of the diabetic population, beta cells die from an autoimmune attack. Both kinds of diabetes lead to severely elevated blood sugar levels that eventually cause a host of possible complications, including loss of limbs and eyesight, kidney damage, diabetic coma, and death.

Most treatments for diabetes focus on insulin, but its counterpart - the hormone glucagon that is produced by alpha cells in the pancreas - has received comparatively little attention, says study leader May-Yun Wang, Ph.D., assistant professor of internal medicine at UTSW. Glucagon binds to receptors on cells in the liver, prompting this organ to secrete glucose. Some recent studies have suggested that depleting glucagon or blocking its receptor can help research animals or humans with diabetes better manage their glucose levels. But how this phenomenon occurs has been unknown.

To answer this question, Wang and her colleagues, including William L. Holland, Ph.D., a former assistant professor of internal medicine at UTSW who is now at the University of Utah, and Philipp E. Scherer, Ph.D., professor of internal medicine and cell biology at UTSW and director of UTSW's Touchstone Center for Diabetes Research, used monoclonal antibodies - manmade proteins that act like human antibodies and help the immune system identify and neutralize whatever they bind to - against the glucagon receptor in mouse models of diabetes.

In one model, called PANIC-ATTAC (pancreatic islet beta-cell apoptosis through targeted activation of caspase 8), a genetic mutation causes beta cells to selectively die off when these mice receive a chemical treatment. Once these animals' beta cells were depleted, the researchers administered monoclonal antibodies against the glucagon receptor. Weekly treatment with the antibodies substantially lowered the rodents' blood sugar, an effect that continued even weeks after the treatments stopped.

Further investigation showed that the number of cells in the pancreas of these animals significantly increased, including beta cells. Searching for the source of this effect, the researchers used a technique called lineage tracing to label their alpha cells. When they followed these alpha cells through rounds of cell divisions, they found that treatment with monoclonal antibodies pushed some of the glucagon-producing alpha cell population to convert into insulin-producing beta cells.

Although the PANIC-ATTAC model shares the same beta cell loss that occurs in both Type 1 and Type 2 diabetes, it's missing the autoimmune attack that spurs Type 1 diabetes. To see if beta cells could rebound through alpha cell conversion under these circumstances, the researchers worked with a different mouse model called nonobese diabetic (NOD) mice in which their beta cells become depleted through an autoimmune reaction. When these animals were dosed with monoclonal antibodies, beta cells returned, despite active immune cells.

In a third animal model that more closely mimics a human system, the researchers injected human alpha and beta cells into immunodeficient NOD mice - just enough cells to produce sufficient insulin to make the animals borderline diabetic. When these mice received monoclonal antibodies against the glucagon receptor, their human beta cells increased in number, protecting them against diabetes, suggesting this treatment could do the same for people.

Holland notes that being able to push alpha cells to shift to beta cells could be especially promising for Type 1 diabetics. "Even after decades of an autoimmune attack on their beta cells, Type 1 diabetics will still have plentiful amounts of alpha cells. They aren't the cells in the pancreas that die," he says. "If we can harness those alpha cells and convert them into beta cells, it could be a viable treatment for anyone with Type 1 diabetes."

Being able to produce native insulin, adds Wang, could hold significant advantages over the insulin injections and pumps used by both Type 1 and Type 2 diabetics. Eventually, she says, similar monoclonal antibodies could be tested in diabetics in clinical trials.

"Even though Type 1 and Type 2 diabetics try their very best to keep glucose under control, it fluctuates quite massively throughout the day even with the best state-of-the-art pump," Wang says. "Giving them back their own beta cells could help restore much better natural regulation, greatly improving glucose regulation and quality of life."

Scherer holds the Gifford O. Touchstone, Jr. and Randolph G. Touchstone Distinguished Chair in Diabetes Research and the Touchstone/West Distinguished Chair in Diabetes Research.

Credit: 
UT Southwestern Medical Center

Antibodies deplete cancer cells in mice and human cell lines; reach previously inaccessible targets

Three studies - one each in Science, Science Translational Medicine, and Science Immunology - reveal the promise of newly engineered bispecific antibodies, including by demonstrating their power against previously inaccessible tumor cell targets for the first time, in two cases. These bispecific antibodies, which simultaneously bind to tumor antigens and T cells, cleared cancer cells without damaging healthy cells in mouse tumor models and/or cell culture experiments, across the three studies. The results highlight the therapeutic potential of this antibody type, which - unlike engineered immune cell therapies like CAR T - does not have to be personalized; it could be used "off-the-shelf."
Some immunotherapy approaches against cancers rely on common cancer-related mutations to serve as antigens; they instigate an immune response to the cancer. Although it is one of the most common mutant tumor suppressor genes known in human cancers, the cancer-related p53 tumor suppressor gene has not been successfully targeted via this approach. This is largely because it is much more challenging to reactivate this and other mutant tumor suppressor genes than it is to deactivate cancer-driving genes. In Science, Emily Han-Chung Hsiue and colleagues successfully engineered a bispecific antibody to reactivate p53. Hsiue et al. first identified a distinct targetable fragment of the mutant tumor suppressor protein and characterized the structural basis for how the fragment is presented to T cells. They developed an antibody that could recognize this fragment of the mutant p53 protein and that did not cross-react with wild-type p53 in intact cells. The researchers then converted this antibody into a bispecific antibody format that attaches one portion to mutant p53 antigen on tumor cells and another to a T cell. In mice engrafted with human multiple myeloma cells, the antibody stimulated effective T cell killing of cancer cells that express the mutant p53 protein, resulting in tumor regression. As well, experiments in cell lines revealed the mutant p53 antigen-targeting bispecific antibody could activate T cells even when the neoantigens were expressed at very low levels on the tumor cell surface.
In Science Translational Medicine, Suman Paul and colleagues employed bispecific antibodies to target malignant T cells in T cell leukemias and lymphomas without harming healthy T cells - a challenging feat in cancer immunotherapy. Therapies that broadly target B cell antigen and cause near complete loss of both healthy and cancerous B cell populations have been remarkably successful and well-tolerated by patients, but broadly targeting T cells in the same way would result in harmful immunosuppression. Paul et al. hypothesized that targeting the beta chain region of T cell receptors could serve as a potential strategy to selectively eliminate malignant T cells while avoiding collateral damage to healthy T cells. They engineered bispecific antibodies to home into either TRBV5-5 or TRBV12, two examples of the 30 beta chains that could be present on malignant T cells. They hypothesized that targeting either beta chain could clear cancer cells without harming healthy T cells that express any of the other 29 beta chain variable regions. In cell lines extracted from patients with T-cell lymphomas and leukemias, application of these bispecific antibodies effectively killed malignant T cells and preserved healthy T cells. Similarly, in mouse models of human T cell cancers, whereby mice received human T cells via intravenous injection, the antibodies promoted killing of malignant T cells without depleting healthy T cells, leading to major tumor regression.
In Science Immunology, Jacqueline Douglass and colleagues modified bispecific antibodies to recognize and kill tumor cells isolated in culture that bear extremely low levels of cancer-driving mutant RAS proteins on their surfaces. Targeting cancer-driving mutant genes like RAS has emerged as a promising strategy for formulating cancer drugs. However, the success of this treatment strategy is limited by the fact that some of these cancer-driving mutant proteins are expressed in low levels on tumor cells, making them incredibly difficult to detect - despite their ubiquity in multiple cancer types. Now, Douglass et al. have used a method called phage display to search for mutant RAS-specific antibodies from a human antibody library. Based on their findings, the researchers developed mutation-associated neoantigen-directed antibodies (MANAbodies) that target mutant RAS neoantigens on tumor cell surfaces. They grafted these mutant RAS-specific MANAbodies onto an optimized T cell-engaging bispecific antibody. Testing the MANAbody-bearing bispecific antibodies in human lung and pancreatic cancer cell lines, the researchers showed the antibodies could specifically recognize and kill tumor cells that bear extremely low levels of mutated RAS proteins, while having no effect on tumor cells that express wild-type or related mutated proteins.
"Although the studies of Hsuie et al., Douglass et al., and Paul et al. are promising for advancing [bispecific antibodies] into the clinic, there are other factors to consider before therapeutic efficacy can be fully realized," Jon Weidanz says. For example, he notes that these antibodies are small molecules that can be rapidly cleared from the blood, which will likely make it necessary to continuously infuse these kinds of drugs with an implanted pump or use other methods to extend the drug's persistence in the blood.

Credit: 
American Association for the Advancement of Science (AAAS)

School-based dental program reduces cavities by more than 50%

image: A new study finds that school-based dental care reduces cavities by more than 50 percent.

Image: 
©Sorel: Courtesy of NYU Photo Bureau

A school-based cavity prevention program involving nearly 7,000 elementary school students reduced cavities by more than 50 percent, according to a study led by researchers at NYU College of Dentistry. The findings are published March 1 in the Journal of the American Dental Association.

"The widespread implementation of oral health programs in schools could increase the reach of traditional dental practices and improve children's oral health--all while reducing health disparities and the cost of care," said Richard Niederman, DMD, professor and chair of the Department Epidemiology & Health Promotion at NYU College of Dentistry and the study's senior author.

Dental cavities are the most common chronic disease in children, and one in five elementary school children have at least one untreated cavity. While cavities can be prevented with dental visits and good at-home oral hygiene, some families experience barriers to seeing a dentist, including cost and parents having to take time off of work.

"School-based cavity prevention programs eliminate these barriers by bringing basic dental care to children, rather than bringing children to care," said Niederman.

The study was conducted in 33 public, high-need elementary schools in Massachusetts, where dental hygienists provided care to 6,927 children. The services were provided at no cost to families.

Twice-yearly visits involved dental examinations followed by cavity prevention and treatment, including fluoride varnish, sealants, and minimally invasive fillings to stabilize cavities without drilling. Students also received oral hygiene instructions, toothbrushes, and fluoride toothpaste to take home. If more complex care was required, students were referred to local dentists. Notably, the procedures used do not create aerosols, which limits the risk of transmitting viruses through the air.

After six visits, the prevalence of untreated cavities decreased by more than 50 percent. In one group of schools, cavities were reduced from a baseline of 39 percent to 18 percent, and in a second group, cavities decreased from 28 percent to 10 percent. The prevention program reduced cavities in both baby and permanent teeth.

"In 2010, the federal government set a goal of reducing the prevalence of cavities in children by 10 percent by 2020. Our study shows that this is not only feasible, but also that a comprehensive school-based program can reduce cavities by five times their goal," said Niederman.

Recent economic analyses of school-based cavity prevention programs by researchers at NYU College of Dentistry, including one focusing on this program in Massachusetts, demonstrate that they are cost-effective and could save federal dollars. If this school-based program was implemented nationally, it could reduce Medicaid spending on children's oral health by as much as one-half.

The COVID-19 pandemic has interrupted most school-based dental care because of school closures and fear of creating aerosols, even as oral health care in dental practices has safely resumed with additional infection control measures in place. The researchers stress the importance of safely continuing school-based care, given its ability to prevent cavities using aerosol-free procedures.

Credit: 
New York University

Future of immunotherapy could be 'off-the-shelf' treatments

image: Jon Weidanz, director of the North Texas Genome Center and associate vice president of research at The University of Texas at Arlington.

Image: 
Randy Gentry/UTA

In a new commentary for the journal Science, an associate vice president for research at The University of Texas at Arlington argues that emerging protein-based immunotherapies could lead to highly effective "off-the-shelf" cancer treatments for more patients.

Jon Weidanz, who also is a professor in the College of Nursing and Health Innovation at UTA, is the author of a perspective regarding the development of cancer immunotherapies.

His article, "Targeting cancer with bispecific antibodies," will appear in the March 5 edition of Science. It evaluates the findings of three studies by researchers at Johns Hopkins University and proposes that an emerging method of protein-based immunotherapy that targets commonly occurring mutations in cancer cells or neoantigens--mutated antigens produced by tumor cells--could lead to treatments that are effective for oncology patients.

Immunotherapy, a method to treat illness by stimulating a person's immune system, is a developing alternative to traditional cancer treatments.

"Up until recently patients were limited to four treatment options: surgery, radiation, chemotherapy and targeted therapy," Weidanz said. "However, the holy grail has always been to develop strategies that would harness the power of the immune system to attack and destroy the cancer. With recent breakthroughs in immuno-oncology along with the new findings being published in Science, it does appear we are closing in on cancer with new immunotherapies."

As medicine has advanced, immunologists have discovered ways to engineer a person's T-cells, the white blood cells that fight and kill infected cells, to recognize and target cancer cells and eliminate them from the body. This approach has led to exciting advances in the field and remission in some patients. However, more work is required to make this form of T-cell therapy more broadly accessible.

Alternatively, researchers have developed approaches that stimulate the immune system without removing T-cells from the body. These "off-the-shelf" protein-based treatments, known as bispecific T-cell engaging antibodies, have proven effective in treating patients with acute lymphoblastic leukemia, a type of blood cancer.

"The ideal is to create protein molecules that have two arms. One arm can recognize the cancer cell and bind to it. The other arm binds to T-cells," Weidanz said. "The protein drug then brings the T-cells into proximity with the tumor cells, which activate the T-cells to destroy the tumor cells."

These two-armed, or bispecific, proteins would avoid healthy cells while destroying cancer cells. Weidanz argues that this method of protein-based immunotherapy could make a difference. The key comes down to the unique targets expressed by the cancer cells that the bispecific protein drug recognizes. Bispecific antibodies could bind to particular neoantigen targets found on tumor cells and recruit T-cells to destroy the cancer.

"The beauty of bispecific proteins is that you could manufacture those proteins and put them on the shelf as an immunotherapy agent," Weidanz said. "If a doctor sees that a patient's cancer expresses the neoantigen target, they could be treated immediately. It's still a personalized medicine, but would not require engineering T-cells."

An expert in immunology, Weidanz has more than 30 years of experience in biotechnology research with an emphasis on immunotherapy, especially related to oncology and product development to diagnose and treat cancer. His research lab at UTA investigates how the immune system identifies malignant cells with the goal of designing treatments that boost immune cells' ability to destroy cancerous cells.

"Dr. Weidanz's substantial expertise in the field of immunology will lead us into the next generation of cancer management," said James Grover, interim vice president of research. "The developments of his lab and those of his many talented colleagues across the nation make this a pivotal moment in the history of a devastating disease."

Weidanz said immunotherapy holds the promise of transforming cancer into a more manageable condition with better prognoses for patients.

"We are getting to a point where we will be able to make cancer more of a chronic disease," Weidanz said. "Now, we look at five-year survival. Maybe we can start looking at 15- or 20-year survival readouts because we're able to manage the disease with immunotherapies that are being developed. It's a very exciting time."

Credit: 
University of Texas at Arlington

Repurposed arthritis drug did not significantly improve severe COVID-19 pneumonia

image: Marketed as Actemra, tocilizumab is approved for treating arthritis and other inflammatory conditions.

Image: 
Photo courtesy of Roche

In a study published online February 25, 2021 in The New England Journal of Medicine, a repurposed drug used to treat arthritis did not significantly improve the outcomes of patients with severe COVID-19 pneumonia.

Results of the Phase III clinical trial, conducted by an international team led by senior author Atul Malhotra, MD, research chief of pulmonary, critical care and sleep medicine at UC San Diego Health, found that tocilizumab did not significantly improve clinical status or mortality rate at 28 days for participants who received it compared to a placebo.

"Although our trial was negative based on primary outcomes, we did see some benefits, including an improvement in length of stay of eight days with tocilizumab compared to placebo, as well as fewer days on the mechanical ventilator with our intervention," said Malhotra.

"Although it is important to be cautious in interpreting secondary outcomes, our trial helped in the design of subsequent studies which do show some improvement in outcomes with tocilizumab, particularly when given in combination with corticosteroids."

Marketed as Actemra, tocilizumab is an immunosuppressive drug used primarily to treat rheumatoid arthritis and systemic juvenile idiopathic arthritis, a severe form of the disease in children. The therapy works by using humanized monoclonal antibodies to specifically target and block cellular receptors for interleukin-6 (IL-6), a small protein or cytokine that plays an important role in triggering inflammation as an early immune response to disease.

In some patients with COVID-19, the immune response runs amok, overexpressing IL-6 and generating a "cytokine storm," which can lead to potentially life-threatening damage to lungs and other organs. Cytokine storms have been linked to a number of inflammatory diseases, from respiratory conditions caused by coronaviruses such as SARS and MERS to some forms of influenza to non-infectious diseases, such as multiple sclerosis and pancreatitis.

Researchers hoped that the heightened role of IL-6 in respiratory diseases and the fact that many severe cases of COVID-19 involve respiratory failure, hospitalization and death pointed to tocilizumab as a potentially effective therapy. Early case reports and retrospective observational studies buttressed that optimism.

The Phase III clinical trial, which began April 2020 and was conducted in 62 hospitals in nine countries, involved 452 patients with confirmed cases of severe COVID-19 pneumonia, randomized into a group of 294 persons who would receive an intravenous infusion of tocilizumab and 144 persons who received a placebo. Malhotra expressed his gratitude to his team at UC San Diego as well as the countless individuals around the world who helped in the execution of a carefully done study.

The researchers found no significant difference in how the two groups fared, and no reduced mortality rate associated with tocilizumab, though they noted the trial was not designed to fully assess that outcome.

No safety issues arose regarding the use of tocilizumab, and the authors said study data suggested the treatment may have some therapeutic benefit during hospital stays and in shortening stays in intensive care units. In both cases, though, they said more research was required.

"Since this trial launched, a lot has been learned about the virus and about how COVID-19 manifests in different people, in different ways and stages," said Malhotra. "These findings need to be understood in that context. We looked at very sick patients. There are very few proven therapies for severe COVID-19. Tocilizumab and some monoclonal antibody treatments may still have utility in specific circumstances, but more work needs to be done.

"In fact, more work must be done. The need for effective treatments for patients with severe COVID-19 pneumonia remains a major challenge of this pandemic. Each new study brings us one step closer to putting that challenge behind us."

Credit: 
University of California - San Diego